A Phase 1 Study in Healthy Volunteers to Investigate Possible Interactions Between RG1662 and Midazolam

Trial Profile

A Phase 1 Study in Healthy Volunteers to Investigate Possible Interactions Between RG1662 and Midazolam

Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2016

At a glance

  • Drugs Basmisanil (Primary) ; Midazolam; Midazolam
  • Indications Down syndrome
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 13 May 2016 The time frame of the PK endpoints have changed from Up to 9 weeks to "re-dose [-0.5 hour (h)] and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 14 h post-dose (pd) on Day (D) 2 and 18, and 22 h pd on D3 and 19"
    • 26 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top